Ditumopa, Rudy D.

HRN: 20-19-46  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/10/2023
CEFTRIAXONE 1G (VIAL)
12/10/2023
12/16/2023
IV
2g
Q24
CAP-MR
Waiting Final Action 
12/10/2023
MUPIROCIN 2%, 15G (TUBE)
12/10/2023
12/17/2023
TOPICAL
2%
BID
Infected Wound
Waiting Final Action 
12/10/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
12/10/2023
12/16/2023
IV
600mg
Q8
CAP MR; Infected Wound
Waiting Final Action 
12/13/2023
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
12/13/2023
12/19/2023
IV
2.25g
Q8
CAP-MR; Infected Wound
Waiting Final Action 
12/19/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
12/19/2023
12/23/2023
IV
600
Q8
Sp BKA
Waiting Final Action 
12/19/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
12/16/2023
12/23/2023
IV
600
Q8
Sp BKA
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: